pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla is a pharma organization headquartered in EU. Primary therapeutic focus areas include Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in supe
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
PHARBEVACOL
Approved · small molecule · 1st line treatment for unresectable metastatic colorectal cancer
PHARBEVACOL for 1st line treatment for unresectable metastatic colorectal cancer is a Approved program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Internal code PHARBEVACOL
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tour Hekla
- Phase
- Approved
- Modality
- small_molecule
- Indication
- 1st line treatment for unresectable metastatic colorectal cancer
- Status
- active
- Trials
- 1